NVDA
NVIDIA
-- 140.110 RGTI
Rigetti Computing
-- 10.0400 TSLA
Tesla
-- 394.940 PLTR
Palantir
-- 68.230 AMD
Advanced Micro Devices
-- 121.840 
NEWS
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Restasis for six months before switching to a single TearCare procedure. Key findings revealed that TearCare resulted in statistically significant improvements in tear break-up time (TBUT) and other dry eye symptoms at both three and six months post-treatment. The study's positive outcomes suggest TearCare as a viable primary or secondary treatment for dry eye disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment